Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
01.03.24
/
50%
€26.20
Target price
01.03.25
€41.56
Performance (%)
7.63%
Price
13.05.24
€27.40
Summary
This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada shows slight gains of 7.63%. This prediction currently runs until 01.03.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | 12.295% | 12.295% |
| iShares Core DAX® | 2.749% | 4.620% |
| iShares Nasdaq 100 | 0.470% | -0.331% |
| iShares Nikkei 225® | -2.930% | -5.556% |
| iShares S&P 500 | 0.679% | 0.631% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.40
03.11.23
03.11.23
€54.04
03.11.24
03.11.24
-2.82%
13.05.24
13.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€27.40
03.10.23
03.10.23
€65.04
03.10.24
03.10.24
2.92%
13.05.24
13.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€34.80
03.08.23
03.08.23
€62.07
03.08.24
03.08.24
-21.26%
13.05.24
13.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24